Therefore, we present the second advantage of our predictive model, which can reflect the mutational status of gliomas, wherein high-risk patients exhibit a lower frequency of IDH1 mutation, 1p/19q co-deletion and MGMT methylation. This evidence concerns the gene IDH1 and central nervous system cancer.